150 related articles for article (PubMed ID: 12101421)
1. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.
Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT
Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of WNT2 and TSG101 genes in colorectal carcinoma.
Ma XR; Edmund Sim UH; Pauline B; Patricia L; Rahman J
Trop Biomed; 2008 Apr; 25(1):46-57. PubMed ID: 18600204
[TBL] [Abstract][Full Text] [Related]
5. TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence.
Feng GH; Lih CJ; Cohen SN
Cancer Res; 2000 Mar; 60(6):1736-41. PubMed ID: 10749147
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
[TBL] [Abstract][Full Text] [Related]
7. Absence of TSG101 transcript abnormalities in human cancers.
Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
[TBL] [Abstract][Full Text] [Related]
8. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
9. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
10. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation.
Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU
Oncogene; 2007 Aug; 26(40):5950-9. PubMed ID: 17369844
[TBL] [Abstract][Full Text] [Related]
11. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
Hosokawa Y; Nagai E; Seto M
J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
13. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.
Turpin E; Dalle B; de Roquancourt A; Plassa LF; Marty M; Janin A; Beuzard Y; de Thé H
Oncogene; 1999 Dec; 18(54):7834-7. PubMed ID: 10618725
[TBL] [Abstract][Full Text] [Related]
14. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
[TBL] [Abstract][Full Text] [Related]
15. p53 induction prevents accumulation of aberrant transcripts in cancer cells.
Moyret-Lalle C; Duriez C; Van Kerckhove J; Gilbert C; Wang Q; Puisieux A
Cancer Res; 2001 Jan; 61(2):486-8. PubMed ID: 11212237
[TBL] [Abstract][Full Text] [Related]
16. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
17. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
18. Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines.
Ferrer M; López-Borges S; Lazo PA
Oncogene; 1999 Apr; 18(13):2253-9. PubMed ID: 10327071
[TBL] [Abstract][Full Text] [Related]
19. Identification of cellular TSG101 protein in multiple human breast cancer cell lines.
Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH
Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081
[TBL] [Abstract][Full Text] [Related]
20. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants.
Wagner KU; Dierisseau P; Rucker EB; Robinson GW; Hennighausen L
Oncogene; 1998 Nov; 17(21):2761-70. PubMed ID: 9840940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
